Trials / Completed
CompletedNCT00989872
Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers
A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Safety, Tolerability, and Pharmacokinetics Study of EDP-322 in Healthy Adult Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Enanta Pharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This was a randomized, double-blind, placebo-controlled, ascending single dose safety, tolerability, and pharmacokinetic study of orally administered EDP-322. This study was conducted at a single site. EDP-322 has a benefit to risk profile that supports testing in target patient populations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EDP-322 |
Timeline
- First posted
- 2009-10-06
- Last updated
- 2009-10-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00989872. Inclusion in this directory is not an endorsement.